Insight Molecular Diagnostics (IMDX) Liabilities and Shareholders Equity (2015 - 2026)

Insight Molecular Diagnostics has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $40.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $40.4 million, down 33.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.6 million (down 33.17% YoY), and the FY2025 annual result was $25.8 million, down 26.58% from the prior year.
• Liabilities and Shareholders Equity came in at $40.4 million for Q1 2026 at Insight Molecular Diagnostics, up from $25.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $171.1 million in Q2 2022 to a low of $25.8 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $74.7 million (2024), against an average of $80.8 million.
• Across the five-year window, Liabilities and Shareholders Equity climbed 13.12% in 2022 and slumped 53.16% in 2024, its largest moves.
• Insight Molecular Diagnostics' Liabilities and Shareholders Equity stood at $100.1 million in 2022, then decreased by 25.18% to $74.9 million in 2023, then plunged by 53.16% to $35.1 million in 2024, then dropped by 26.58% to $25.8 million in 2025, then jumped by 56.96% to $40.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $40.4 million (Q1 2026), $25.8 million (Q4 2025), and $43.9 million (Q3 2025), per Business Quant data.